AnGes

AnGes MG,Inc. Global leader in gene Medical

Select Language

NAVIGATION

Corporate Information

Company Profile

Corporate name AnGes, Inc.
Head office 1F, Saito Bio-Incubator, 7-7-15, Saito-asagi, Ibaraki, Osaka,
567-0085 Japan
Established December 17, 1999
President and CEO Ei Yamada
Capitalization 13,274 million yen (as of June 30, 2019)
Outstanding shares 106,925,061 shares (as of June 30, 2019)
Number of employees 38 (as of June 30, 2019, Consolidated)
Scope of business Research & development of gene-based medical products

History

December 1999 Founded as MedGene Co., Ltd. in Izumi-city, Osaka for research and development of gene and nucleotide based drugs and reagents for use in functional analyses of genetic medication.
June 2000 Changed corporate name to MedGene Bioscience Co., Ltd.
August 2000 Formed partnership with Ishihara Sangyo Kaisha, Ltd. on manufacturing and marketing of HVJ envelope vectors.
January 2001 Established Ikeda Laboratory in Ikeda-city, Osaka.
January 2001 Established Tokyo branch in Minato-ku, Tokyo.
July 2001 Moved head office to Toyonaka-city, Osaka.
October 2001 Changed corporate name to AnGes MG, Inc.
October 2001 Founded AnGes, Inc. in the state of Maryland for clinical development in the US.
June 2002 Founded AnGes, Euro Ltd. (business development in Europe) in the county of Sussex, UK.
July 2002 Founded GenomIdea Inc. in Toyonaka-city, Osaka for gene function analyses.
September 2002 IPO: AnGes MG achieved listing on the Mothers markets of Tokyo Stock Exchange.
February 2003 Moved head office of AnGes, Euro Ltd. to Surrey, UK.
September 2003 Transferred HVJ envelope vectors business to GenomIdea, Inc.
September 2004 Moved head office to Ibaraki-city, Osaka.
September 2004 Moved head office of GenomIdea Inc. to Ibaraki-city, Osaka.
December 2006 Formed partnership with BioMarin Pharmaceutical, Inc. on marketing and distribution of a product approved in the US, “Naglazyme®” (gulsulfase) for treatment of the genetic disease mucopolysaccharidosis VI in Japan.
April 2008 Launched "Naglazyme®" for treatment of mucopolysaccharidosis VI in Japan.
January 2013 Transferred the stock in GenomIdea, Inc. to Ishihara Sangyo Kaisha, Ltd.
July 2017 Changed corporate name to AnGes, Inc.
January 2018 HGF Plasmid Marketing approval application submitted

PageTop

  • News Release
  • About AnGes
  • Projects
  • For Investors
  • HomeSite mapPrivacy PolicySite PolicyContact
  • Copyright© AnGes, Inc. All Rights Reserved.